300+ Studies Manage Risks with CluePoints COVID-19 Support
CluePoints, a provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, announced 183 studies across 22 sponsor and CRO organizations have taken advantage of CluePoints complimentary COVID-19 risk management package alongside comprehensive support for COVID-19 affected trials. Launched in April in the wake of COVID-19, the support package includes an online Risk Assessment and Control solution that can be leveraged for performing risk planning and mitigation activities addressing inherent risks during this crisis.
With sponsors and CROs facing a myriad of new recommendations and guidelines issued by the FDA, EMA, PMDA, MHRA and other local agencies due to coronavirus, the complimentary support package was offered to sponsors and CROs to keep up with the need to assess and control risk on new and ongoing studies, with documentation and audit trails even more important in this highly dynamic environment.
CluePoints has been commissioned to provide deeper analytical support to a further 135 studies.
Commenting on the support package, Patrick Hughes, Co-Founder and Chief Commercial Officer of CluePoints said, “We have also seen a significant increase in existing clients stepping up their data analysis to ensure early detection of issues needing urgent attention.”
In addition, CluePoints solutions have also been utilized in over 12 high-profile specific COVID-19 vaccine studies with leading pharma sponsors in conjunction with their top five CRO development partners.
Source: CluePoints
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
